A randomized, prospective, active-controlled study comparing intramuscular long-acting paliperidone palmitate versus oral antipsychotics in patients with schizophrenia at risk of violent behavior

被引:1
|
作者
Wang, Gang [1 ]
Huang, Huiteng [1 ]
Wang, Yijun [1 ]
Yang, Yongde [1 ]
Li, Chang [1 ]
Luo, Sen [1 ]
Li, Yi [1 ,2 ]
机构
[1] Wuhan Mental Hlth Ctr, Wuhan, Peoples R China
[2] Wuhan Mental Hlth Ctr, 89 Gongnongbing Rd, Wuhan, Hubei, Peoples R China
关键词
Schizophrenia; Violence; Aggression; Paliperidone palmitate; Community-based; INJECTABLE ANTIPSYCHOTICS; MEDICATION ADHERENCE; FAMILY CAREGIVERS; SOCIAL COGNITION; BURDEN; PREVALENCE; CHINA;
D O I
10.1016/j.pnpbp.2023.110897
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Paliperidone palmitate (PP) is an effective long-acting antipsychotic injection, but its impact on the behavior of schizophrenia patients with dangerous tendencies requires further investigation. This study aims to explore the effects of long-term antipsychotic treatment on this population in the community.Methods: This 49-week, randomized controlled trial was conducted across 21 communities in Wuhan and enrolled 134 schizophrenia patients at risk for violent behavior. With a fixed block size of 10, participants were randomly assigned to receive either intramuscular PP 1-month formulation (PP1M) or oral antipsychotic medication (OAP) at a 1:1 ratio. Changes in patients' risk for violent/aggressive behavior, family burden, social, and cognitive functioning were measured using VRAPP, MOAS, PANSS, FBS, PSP, and RBANS scales from baseline to endpoint. Longitudinal data from multiple repeated measures were analyzed using linear mixed-effects models.Results: The study protocol was completed by 77.6% of the patients overall. Significant improvements were observed in the risk assessment scores, MOAS total score, PANSS total score, PSP total score, and FBS total score of patients in the PP1M group from baseline to the end of treatment (all P < 0.05). Importantly, compared to patients in the OAP group, the improvements in these measures were also significantly greater in the PP1M group. Commonly observed AEs, such as hyperprolactinemia (70.3% vs. 62.65%) and muscle tension (45.3% vs. 57.8%), were considered to be the PP-related AEs. Nonetheless, the differences between the two groups did not reach statistical significance, and no new safety concerns emerged.Conclusions: Our study suggests that PP long-acting injection (LAI) is a safe and effective treatment option for community-dwelling schizophrenia patients with impulsive violence and risky behaviors.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] A comparative randomized, open-label, rater-blinded study of paliperidone palmitate and risperidone long-acting injectable therapy in patients with schizophrenia
    Li, H.
    Rui, Q.
    Ning, X.
    Xu, H.
    Gu, N.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 : 167 - 167
  • [42] Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine
    McDonnell, David P.
    Kryzhanovskaya, Ludmila A.
    Zhao, Fangyi
    Detke, Holland C.
    Feldman, Peter D.
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2011, 26 (06) : 422 - 433
  • [43] Clinical and functional outcomes of patients with schizophrenia treated with risperidone long-acting injection versus oral antipsychotics
    Olivares, J. M.
    Morales, A. Rodriguez
    Diels, J.
    Povey, M.
    Lam, A.
    Zhao, Z.
    EUROPEAN PSYCHIATRY, 2008, 23 : S126 - S127
  • [44] Risk of withdrawal of consent for treatment with long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled trials
    Yaegashi, Hodaka
    Misawa, Fuminari
    Noda, Hokuto
    Fujii, Yasuo
    Takeuchi, Hiroyoshi
    SCHIZOPHRENIA RESEARCH, 2021, 229 : 94 - 101
  • [45] Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder
    Greene, Mallik
    Yan, Tingjian
    Chang, Eunice
    Hartry, Ann
    Touya, Maelys
    Broder, Michael S.
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (02) : 127 - 134
  • [46] The effects of risperidone long-acting injection versus paliperidone palmitate on cognitive and social function in schizophrenia - an open pilot randomised controlled trial
    Koshikawa, Y.
    Takekita, Y.
    Kato, M.
    Sakai, S.
    Onohara, A.
    Sunada, N.
    Nishida, K.
    Yoshimura, M.
    Fabbri, C.
    Serretti, A.
    Kinoshita, T.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 : S500 - S501
  • [47] Benzodiazepines and Mood Stabilizers in Schizophrenia Patients Treated with Oral versus Long-Acting Injectable Antipsychotics-An Observational Study
    Miron, Ana Aliana
    Petric, Paula Simina
    Teodorescu, Andreea
    Ifteni, Petru
    Chele, Gabriela
    Szalontay, Andreea Silvana
    BRAIN SCIENCES, 2023, 13 (02)
  • [48] Efficacy and quality of life in patients with schizophrenia and schizoaffective disorders treated with long-acting paliperidone palmitate: A naturalistic longitudinal study
    Nivoli, A.
    Folini, L.
    Floris, L.
    Antonioli, M.
    Pinna, F.
    Paolo, M.
    Bernardo, C.
    Liliana, L.
    EUROPEAN PSYCHIATRY, 2017, 41 : S274 - S274
  • [49] COMPARING risperidone long-acting injection (RLAI) with oral antipsychotics in Spanish patients with schizophrenia using propensity scoring
    Diels, J.
    Olivares, J. M.
    Rodriguez-Morales, A.
    Caleo, S.
    EUROPEAN PSYCHIATRY, 2007, 22 : S110 - S111
  • [50] Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies
    Michael Markowitz
    Dong-Jing Fu
    Bennett Levitan
    Srihari Gopal
    Ibrahim Turkoz
    Larry Alphs
    Annals of General Psychiatry, 12